Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Barinthus Biotherapeutics ( (BRNS) ) just unveiled an update.
On December 30, 2025, Barinthus Biotherapeutics plc received a notice from Nasdaq that the closing bid price of its American Depositary Shares had remained below $1.00 for 30 consecutive business days, placing the company out of compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. While the ADSs remain listed and trading is unaffected in the near term, Barinthus now has until June 29, 2026, to restore its share price to at least $1.00 for ten consecutive business days or risk potential delisting, and the company is monitoring its stock performance and considering options such as a reverse stock split to regain compliance, which could have implications for existing shareholders and the company’s market standing.
The most recent analyst rating on (BRNS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Barinthus Biotherapeutics stock, see the BRNS Stock Forecast page.
Spark’s Take on BRNS Stock
According to Spark, TipRanks’ AI Analyst, BRNS is a Neutral.
Barinthus Biotherapeutics faces significant financial and technical challenges, with ongoing losses and bearish market momentum. While the AVALON trial progress is promising, it does not offset the immediate financial and valuation concerns.
To see Spark’s full report on BRNS stock, click here.
More about Barinthus Biotherapeutics
Barinthus Biotherapeutics plc is a biotechnology company whose American Depositary Shares (ADSs), each representing one ordinary share, are listed on the Nasdaq Global Market under the symbol “BRNS.”
Average Trading Volume: 94,209
Technical Sentiment Signal: Sell
Current Market Cap: $29.69M
For detailed information about BRNS stock, go to TipRanks’ Stock Analysis page.